Gonda Kenji, Shibata Masahiko, Shimura Tatsuo, Abe Noriko, Suzuki Satoshi, Yasuda Mitsuhiko, Nakamura Izumi, Ohtake Tohru, Ohki Shinji, Watanabe Takafumi, Fujimori Keiya, Suzuki Shinichi, Ohto Hitoshi, Takenoshita Seiichi
Dept. of Organ Regulatory Surgery, Fukushima Medical University, Japan.
Gan To Kagaku Ryoho. 2012 Nov;39(12):2088-91.
Myeloid-derived suppressor cells(MDSCs) have been reported to be induced by inflammation, to suppress immune function, and promote tumor progression, and to be found in circulating blood, tumor tissue, and lymph nodes. MDSCs were found in pleural effusions and ascites of patients with malignant diseases and these results are described in this report. Changes in the levels of MDSCs during clinical responses to cancer chemotherapy are also reported. MDSC levels in malignant effusions have also been shown to change with the levels of MDSCs in peripheral blood and with clinical responses. MDSCs seem to play an important role in inflammation that is strongly related to advancing malignant diseases. The results also suggested that MDSCs may be reduced after effective chemotherapy, which may be effective as an adjuvant treatment with cancer immunotherapy.
据报道，髓源性抑制细胞（MDSCs）可由炎症诱导产生，具有抑制免疫功能、促进肿瘤进展的作用，且在循环血液、肿瘤组织及淋巴结中均可发现。在恶性疾病患者的胸腔积液和腹水中也发现了MDSCs，本报告将对此结果进行描述。同时也报道了癌症化疗临床反应过程中MDSCs水平的变化。恶性积液中的MDSCs水平也已显示出与外周血中MDSCs水平及临床反应相关。MDSCs似乎在与恶性疾病进展密切相关的炎症中发挥重要作用。结果还表明，有效化疗后MDSCs可能减少，这可能作为癌症免疫治疗的辅助治疗有效。
